伴隨診斷合作與授權協議（2010-2025）

伴隨診斷合作與許可協議報告全面深入地分析了全球領先的生物製藥公司簽署的伴隨診斷協議，並提供前所未有的查閱途徑。

這份經過全面修訂和更新的報告詳細介紹了2010年至2025年間的伴隨診斷協議。

本報告深入分析了企業簽訂伴隨診斷協議的原因和方式。這些協議通常涵蓋多個方面，從合作研發到成果商業化。

本報告涵蓋合作、開發、研究和授權等內容。

本報告包​​含自2010年以來公佈的545項伴隨診斷協議的完整清單，其中包括可用的財務條款以及各方披露的實際伴隨診斷合作協議的在線記錄鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了伴隨診斷交易。

第一章概述了本報告。

第二章概述了自 2010 年以來伴隨診斷交易活動。

第三章概述了自 2010 年以來主要的伴隨診斷交易，並依交易額列出。

第四章提供了伴隨診斷交易中最活躍的 25 家公司的完整列表，並附有簡要概述，隨後提供了伴隨診斷交易和公開合約文件的完整列表。

第五章對自 2010 年 1 月以來簽署和宣布的、合約文件公開的伴隨診斷交易進行了全面深入的審查。

第六章對自2010年1月以來簽署和公佈的伴隨診斷合作協議進行了全面深入的回顧。本章依具體的伴隨診斷技術類型進行組織。

報告還包含大量表格和圖表，展示了自2010年以來伴隨診斷交易的趨勢和活動。

此外，我們還提供了一個全面的協議目錄，依公司名稱（A-Z）、協議類型和治療靶點進行分類。每個協議標題都透過網路連結指向線上協議記錄，並在可用的情況下指向協議文件，以便根據需要輕鬆存取每個協議文件。

主要優勢

伴隨診斷合作開發和授權協議分析報告為讀者提供以下主要優勢：

• 了解自 2010 年以來的交易趨勢
• 瀏覽伴隨診斷合作與授權協議
• 基準分析 - 確定交易市場價值
• 財務條款 - 初始費用、里程碑付款、特許權使用費
• 依公司（A-Z）、交易類型和治療領域分類的交易目錄
• 以價值排名的主要交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

範圍

• 伴隨診斷合作和許可協議報告是旨在幫助讀者深入了解伴隨診斷的發展趨勢以及全球主要生物製藥公司簽訂的協議結構。

伴隨診斷的合作與授權協議包括：

• 生物製藥產業伴隨診斷交易趨勢
• 製藥和生物技術公司伴隨診斷協議記錄目錄
• 依價值劃分的主要伴隨診斷協議
• 最活躍的伴隨診斷許可協議公司
• 伴隨診斷的合作與許可協議提供對可用協議記錄的全面訪問，包括合約文件（如有）。

分析協議有助於對以下方面進行盡職調查：

• 協議具體授予或選擇哪些權利？
• 協議實際授予合作夥伴哪些權利？
• 授予了哪些排他性權利？
• 交易的付款結構是什麼？
• 銷售和付款如何審計？
• 合約期限是多久？
• 合約的關鍵條款是如何定義的？
• 智慧財產權（IPR）如何處理歸屬於誰？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果所有權發生變更，會發生什麼事？
• 如何約定轉讓許可和分包條款？
• 貴公司要求使用哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司必須在哪個司法管轄區管轄其合約？

目錄

摘要整理

第一章：引言

第二章：伴隨診斷交易趨勢

• 引言
• 伴隨診斷交易歷年回顧
• 最活躍的伴隨診斷經銷商
• 依交易類型劃分的伴隨診斷交易
• 依治療領域劃分的伴隨診斷交易
• 依行業劃分的伴隨診斷交易
• 伴隨診斷交易條款
  • 伴隨診斷交易的關鍵價值因素
  • 伴隨診斷合約的預付款
  • 伴隨診斷交易的里程碑付款
  • 伴隨診斷特許權使用費價格

第三章 - 主要伴隨診斷交易

• 引言
• 以價值排名的頂級伴隨診斷交易

第四章 - 最活躍的伴隨診斷交易商

• 引言
• 最活躍的伴隨診斷經銷商
• 最活躍伴隨診斷交易的公司簡介

第五章 - 伴隨診斷合約交易目錄

• 引言
• 伴隨診斷合約交易目錄

第六章 - 依技術類型劃分的伴隨診斷交易

• 交易目錄
• 交易目錄 - 依公司劃分的伴隨診斷交易 (AZ)
• 交易目錄- 依交易類型分類的伴隨診斷交易
• 交易目錄 - 依治療領域分類的伴隨診斷交易
• 交易類型定義
• 關於研究公司
• 當前合作夥伴
• 當前合約
• 依目前合作夥伴分類的最新報告標題

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 545 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2010
• Browse companion diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:

• Trends in companion diagnostic dealmaking in the biopharma industry
• Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
• The leading companion diagnostic deals by value
• Most active companion diagnostic licensing dealmakers
• Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in companion diagnostic dealmaking

• 2.1. Introduction
• 2.2. Companion diagnostic deals over the years
• 2.3. Most active companion diagnostic dealmakers
• 2.4. Companion diagnostic deals by deal type
• 2.5. Companion diagnostic deals by therapy area
• 2.6. Companion diagnostic deals by industry sector
• 2.7. Deal terms for companion diagnostic deals
  • 2.7.1 Companion diagnostic deals headline values
  • 2.7.2 Companion diagnostic deal upfront payments
  • 2.7.3 Companion diagnostic deal milestone payments
  • 2.7.4 Companion diagnostic royalty rates

Chapter 3 - Leading companion diagnostic deals

• 3.1. Introduction
• 3.2. Top companion diagnostic deals by value

Chapter 4 - Most active companion diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active companion diagnostic dealmakers
• 4.3. Most active companion diagnostic deals company profiles

Chapter 5 - Companion diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 - Companion diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Companion diagnostic deals by company A-Z
• Deal directory - Companion diagnostic deals by deal type
• Deal directory - Companion diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Companion diagnostic deals since 2016
• Figure 2: Active companion diagnostic dealmaking activity - 2016 - 2025
• Figure 3: Companion diagnostic deals by deal type since 2016
• Figure 4: Companion diagnostic deals by therapy area since 2016
• Figure 5: Companion diagnostic deals by industry sector since 2016
• Figure 6: Companion diagnostic deals with a headline value
• Figure 7: Companion diagnostic deals with an upfront value
• Figure 8: Companion diagnostic deals with a milestone value
• Figure 9: Companion diagnostic deals with a royalty rate value
• Figure 10: Top companion diagnostic deals by value since 2016
• Figure 11: Most active companion diagnostic dealmakers 2016 - 2025
• Figure 12: Companion diagnostic deals by technology type since 2016